Galectin ‐9 alleviates acute graft‐versus‐host disease after haplo‐hematopoietic stem cell transplantation by regulating regulatory T cell/effector T cell imbalance

ConclusionGalectin-9 may ameliorate aGVHD after haplo-HSCT by modulating Treg/Teffs balance and regulating the PI3K/AKT/mTOR pathway. Targeting Galectin-9 may hold potential value for the treatment of aGVHD.

Source: Immunity, Inflammation and Disease - February 14, 2024 Category: Allergy & Immunology Authors: Nannan Pang, Shabaaiti Tudahong, Yuejie Zhu, Jiang He, Chunxia Han, Gang Chen, Weiguo Wang, Jing Wang, Jianbing Ding Tags: ORIGINAL ARTICLE Source Type: research